The models can help find better inhibitors for conditions like baldness and prostate disorders.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
July 2013 in “Edinburgh Research Archive (University of Edinburgh)” Dutasteride may reduce insulin sensitivity and increase body fat.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
The document concludes that hair loss in women can be treated with topical treatments or hormone therapy depending on the cause.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.